Detalhe da pesquisa
1.
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants.
Antimicrob Agents Chemother
; 68(1): e0078123, 2024 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38038460
2.
Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.
HIV Med
; 25(3): 381-390, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38147871
3.
Efficacy, safety, and pharmacokinetics by BMI category in Phase 3/3b cabotegravir + rilpivirine long-acting trials.
J Infect Dis
; 2023 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38134313
4.
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Clin Infect Dis
; 76(9): 1646-1654, 2023 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36660819
5.
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Clin Infect Dis
; 77(10): 1423-1431, 2023 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37340869
6.
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
N Engl J Med
; 382(12): 1124-1135, 2020 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32130806
7.
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
N Engl J Med
; 382(12): 1112-1123, 2020 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32130809
8.
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials.
HIV Med
; 24(5): 568-579, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36411596
9.
Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two-drug regimen in SWORD-1/-2 phase 3 studies.
Br J Clin Pharmacol
; 89(7): 2190-2200, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36740580
10.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet
; 396(10267): 1994-2005, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33308425
11.
Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.
J Antimicrob Chemother
; 75(3): 648-655, 2020 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31873746
12.
Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection.
Antimicrob Agents Chemother
; 62(9)2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29987139
13.
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Lancet
; 390(10101): 1499-1510, 2017 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28750935
14.
Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers.
Int J Clin Pharmacol Ther
; 52(2): 118-28, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24161160
15.
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
Lancet HIV
; 11(4): e222-e232, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538161
16.
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Lancet HIV
; 11(4): e211-e221, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538160
17.
Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.
Antimicrob Agents Chemother
; 57(11): 5472-7, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23979733
18.
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
Ther Adv Infect Dis
; 10: 20499361231214626, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38107552
19.
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Lancet
; 378(9787): 229-37, 2011 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-21763935
20.
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Lancet
; 378(9787): 238-46, 2011 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-21763936